{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:45:23Z","timestamp":1771231523244,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.urology.2013.12.027","type":"journal-article","created":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T21:45:45Z","timestamp":1393451145000},"page":"1023-1029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Do Patient Characteristics Predict Responsiveness to Treatment of Overactive Bladder With Antimuscarinic Agents?"],"prefix":"10.1016","volume":"83","author":[{"given":"Sender","family":"Herschorn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fady","family":"Ntanios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2013.12.027_bib1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MOU.0b013e32832ce8a4","article-title":"Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence","volume":"19","author":"Andersson","year":"2009","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urology.2013.12.027_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2013.12.027_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eursup.2011.01.004","article-title":"Understanding dose titration: overactive bladder treatment with fesoterodine as an example","volume":"10","author":"Michel","year":"2011","journal-title":"Eur Urol Supplem"},{"key":"10.1016\/j.urology.2013.12.027_bib4","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1464-410X.2009.08545.x","article-title":"Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome","volume":"104","author":"Chapple","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2013.12.027_bib5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.urology.2007.12.017","article-title":"Fesoterodine dose response in subjects with overactive bladder syndrome","volume":"71","author":"Khullar","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.urology.2013.12.027_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1464-410X.2010.09587.x","article-title":"Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study","volume":"107","author":"Wyndaele","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2013.12.027_bib7","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/nau.21099","article-title":"Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder","volume":"30","author":"Staskin","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2013.12.027_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1464-410X.2009.09086.x","article-title":"Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a\u00a0head-to-head placebo-controlled trial","volume":"105","author":"Herschorn","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2013.12.027_bib9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1464-410X.2010.09640.x","article-title":"Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a\u00a0prospective, head-to-head, placebo-controlled trial","volume":"107","author":"Kaplan","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2013.12.027_bib10","first-page":"1027","article-title":"Does gender or age affect the efficacy and safety of tolterodine?","volume":"168","author":"Michel","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2013.12.027_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/j.1742-1241.2010.02442.x","article-title":"Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?","volume":"64","author":"Schneider","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.urology.2013.12.027_bib12","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.urology.2010.03.097","article-title":"Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder","volume":"76","author":"Kraus","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urology.2013.12.027_bib13","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1464-410X.2010.09202.x","article-title":"Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?","volume":"106","author":"Cardozo","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2013.12.027_bib14","series-title":"Toviaz\u00ae(fesoterodine fumarate). Full Prescribing Information","year":"2011"},{"key":"10.1016\/j.urology.2013.12.027_bib15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.urology.2013.12.027_bib16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/nau.21005","article-title":"Validation of the urinary sensation scale (USS)","volume":"30","author":"Coyne","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2013.12.027_bib17","unstructured":"World Health Organization. BMI classification. Available at: http:\/\/apps.who.int\/bmi\/index.jsp?introPage=intro_3.html. Accessed May 15,\u00a02012."},{"key":"10.1016\/j.urology.2013.12.027_bib18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11934-003-0025-z","article-title":"Overactive bladder: improving the efficacy of anticholinergics by dose escalation","volume":"4","author":"MacDiarmid","year":"2003","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urology.2013.12.027_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0090-4295(02)01800-9","article-title":"Influence of behavior modification on overactive bladder","volume":"60","author":"Burgio","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urology.2013.12.027_bib20","first-page":"2455","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA.SUFU guideline","volume":"188","author":"Gormely","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2013.12.027_bib21","first-page":"752","article-title":"Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity","volume":"171","author":"Landis","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2013.12.027_bib22","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1464-410X.2011.10436.x","article-title":"Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting","volume":"109","author":"Asche","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2013.12.027_bib23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0029-7844(00)00915-7","article-title":"Risk factors for lower urinary tract symptoms in women 40 to 60 years of age","volume":"96","author":"Alling Moller","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.urology.2013.12.027_bib24","first-page":"S2","article-title":"Obesity and urinary incontinence: epidemiology and clinical research update","volume":"182","author":"Subak","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2013.12.027_bib25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2296-10-8","article-title":"Prevalence, evaluation and management of overactive bladder in primary care","volume":"10","author":"Cheung","year":"2009","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.urology.2013.12.027_bib26","first-page":"955","article-title":"The association of adiposity and overactive bladder appears to differ by gender: results from the Boston Area Community Health survey","volume":"185","author":"Link","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2013.12.027_bib27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1471-0528.2004.00137.x","article-title":"Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women","volume":"111","author":"Teleman","year":"2004","journal-title":"BJOG"},{"key":"10.1016\/j.urology.2013.12.027_bib28","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1079\/PHN2004627","article-title":"The association of diet and other lifestyle factors with the onset of overactive bladder: a longitudinal study in men","volume":"7","author":"Dallosso","year":"2004","journal-title":"Public Health Nutr"},{"key":"10.1016\/j.urology.2013.12.027_bib29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/nau.20787","article-title":"Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release","volume":"29","author":"Chancellor","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2013.12.027_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF02765589","article-title":"The relationship of body mass index to intra-abdominal pressure as measured by multichannel cystometry","volume":"8","author":"Noblett","year":"1997","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429513016142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429513016142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:57:28Z","timestamp":1758765448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429513016142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0090429513016142"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2013.12.027","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do Patient Characteristics Predict Responsiveness to Treatment of Overactive Bladder With Antimuscarinic Agents?","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2013.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}